but out price, page-136

My friend, I was responding to a very bullish take on what I had said, which I didn't want to be taken out of context. While there is a substantial amount of data known for Bisantrene that demonstrates very clear value, the issue I have is that there is so much data still to come out for Bisantrene and FTO, which makes it hard for me to knuckle down on accurate numbers or potential value (it's huge). I am working on a valuation model based on peer comparisons (why not compare to what pharma companies have paid before), but because I want it to be extremely solid, it is taking some time.

Based on numerous lines of evidence that I will discuss in time, I believe that Bisantrene can achieve the largest pharmaceutical buyout for a single drug ever recorded and remain that way for a long time. I have said this before and nothing has changed.